Lumos Diagnostics (ASX: LDX) announced that it has entered into three new agreements with US-based women’s healthcare company Hologic that will provide Lumos with up to US$5.9 million in total in non-dilutive funding. This includes $4.2m from the sale and leaseback agreement for some of Lumos’ capital equipment, and $1.7m from additional work on existing projects.
Also a few more products in line for release to the US market ViraDX Trading halt this week
